Table 2.

Univariate analysis of variables predictive of PFS and OS

	PFS		OS
Variables	HR (95% CI)	P value	HR (95% CI)	P value
Sex (Male vs. Female)	1.273 (0.831–1.948)	0.267	0.917 (0.541–1.555)	0.747
Age (≤60 vs. > 60)	1.470 (0.843–2.565)	0.174	1.296 (0.658–2.553)	0.453
Ann Arbor stage		< 0.001		< 0.001
I	Reference		Reference
II	1.894 (1.072–3.348)	0.028	2.123 (1.027–4.390)	0.042
III-IV	3.843 (2.247–6.573)	< 0.001	4.998 (2.551–9.791)	< 0.001
Primary site (UADT vs. Extra-UADT)	1.388 (0.754–2.554)	0.292	1.612 (0.818–3.179)	0.168
B symptoms (No vs. Yes)	1.703 (1.109–2.616)	0.015	1.778 (1.055–2.995)	0.031
LDH (Normal vs. Elevated)	3.014 (1.928–4.711)	< 0.001	3.923 (2.267–6.791)	< 0.001
β2-MG (Normal vs. Elevated)	2.486 (1.639–3.772)	< 0.001	2.788 (1.687–4.609)	< 0.001
Hb (≥120 g/L vs < 120 g/L)	2.157 (1.388–3.352)	< 0.001	1.879 (1.110–3.182)	0.019
SUVmax (≤9.5 vs. > 9.5)	2.971 (1.824–4.839)	< 0.001	4.033 (2.088–7.791)	< 0.001
Interim DS (1–3 vs. 4–5)	2.738 (1.393–5.379)	0.003	3.436 (1.554–7.595)	0.002
End-of-treatment DS (1–3 vs. 4–5)	6.707 (2.234–20.14)	< 0.001	5.237 (1.412–19.43)	0.007

Abbreviations: CI confidence interval, HR hazard ratio, PFS progression-free survival, OS overall survival, UADT upper aerodigestive tract, LDH lactate dehydrogenase, β2-MG β2-microglobulin, Hb hemoglobin, DS Deauville score